CNN highlights the significant advancements in medicine discovery through AI, particularly by LabGenius, a London-based company using automated systems to rapidly create and test unique therapeutic molecules. Their innovative approach allows for the design and experimentation of molecular antibodies much faster than traditional methods, leading to the development of novel molecules with over 400x improvement in targeting cancer cells selectively. LabGenius aims to introduce their first therapeutics in clinics by 2027, with potential future applications addressing aging-related conditions.
